Histone deacetylase 3 represses p15INK4b and p21WAF1/cip1 transcription by interacting with Sp1

Huang, Weifeng; Tan, Dapeng; Wang, Xiuli; Han, ShouWei; Tan, Jing; Zhao, Yanmei; Lü, Jun; Huang, Baiqu

doi:10.1016/j.bbrc.2005.11.010

Cited by 42 publications

(33 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Effects similar to those induced by HDAC3 were observed for HDAC1 and -2, with HDAC1 and -2 silencing resulting in reduced cell growth, enhanced cell survival, and p21 induction in a Sp1/Sp3-dependent manner. Supporting our results, a recently published study demonstrated that HDAC1 and HDAC3 overexpression represses p21 expression in an Sp1-dependent manner in cells of nonintestinal epithelial origin (36).…”

Section: Discussionsupporting

confidence: 91%

Histone Deacetylase 3 (HDAC3) and Other Class I HDACs Regulate Colon Cell Maturation and p21 Expression and Are Deregulated in Human Colon Cancer

Wilson

Byun

Попова

et al. 2006

Journal of Biological Chemistry

515

405

View full text Add to dashboard Cite

Inhibitors of histone deacetylases (HDACs) induce growth arrest, differentiation, and apoptosis of colon cancer cell lines in vitro and have demonstrated anti-cancer efficacy in clinical trials. Whereas a role for HDAC1 and -2 in mediating components of the HDAC inhibitor response has been reported, the role of HDAC3 is unknown. Here we demonstrate increased protein expression of HDAC3 in human colon tumors and in duodenal adenomas from Apc1638 N/؉ mice. HDAC3 was also maximally expressed in proliferating crypt cells in normal intestine. Silencing of HDAC3 expression in colon cancer cell lines resulted in growth inhibition, a decrease in cell survival, and increased apoptosis. Similar effects were observed for HDAC2 and, to a lesser extent, for HDAC1. HDAC3 silencing also selectively induced expression of alkaline phosphatase, a marker of colon cell maturation. Concurrent with its effect on cell growth, overexpression of HDAC3 and other Class I HDACs inhibited basal and butyrate-induced p21 transcription in a Sp1/Sp3-dependent manner, whereas silencing of HDAC3 stimulated p21 promoter activity and expression. However, the magnitude of the effects elicited by silencing of individual Class I HDACs was significantly less than that induced by HDAC inhibitors. These findings identify HDAC3 as a gene deregulated in human colon cancer and as a novel regulator of colon cell maturation and p21 expression. These findings also demonstrate that multiple Class I HDACs are involved in repressing p21 and suggest that the growthinhibitory and apoptotic effects induced by HDAC inhibitors are probably mediated through the inhibition of multiple HDACs.Acetylation of DNA-bound core histones and sequence-specific transcription factors is a fundamental mechanism of transcriptional regulation. Histone acetylation is typically associated with increased transcription (1) and is regulated by two opposing classes of enzymes: histone acetyltransferases, which add acetyl groups to specific amino acids of the histone protein, and histone deacetylases (HDACs), 2 which catalyze their removal. A second mechanism by which HDACs may regulate gene transcription is by regulating acetylation of DNA sequence-specific transcription factors. Examples include p53, E2F, and Sp3, where deacetylation has been linked to reduced DNA binding or transcriptional activity (2-4). Through these mechanisms, HDACs are emerging as critical regulators of cell growth, differentiation, and apoptotic programs. We and others have demonstrated that inhibitors of HDACs, such as sodium butyrate, trichostatin A (TSA), suberoylanilide hydroxamic acid (SAHA), and valproic acid, induce cell cycle arrest, differentiation, and apoptosis in colon cancer cell lines in vitro (5-10). These observations suggest a physiological role for transcriptional repression mediated by HDACs in maintaining cell proliferation and survival and inhibiting differentiation. Correspondingly, the deregulation of HDAC-mediated transcriptional repression has been linked to tumorigenesis. The up-regulated e...

show abstract

Section: Discussionsupporting

confidence: 91%

Histone Deacetylase 3 (HDAC3) and Other Class I HDACs Regulate Colon Cell Maturation and p21 Expression and Are Deregulated in Human Colon Cancer

Wilson

Byun

Попова

et al. 2006

Journal of Biological Chemistry

515

405

View full text Add to dashboard Cite

show abstract

“…HDAC3 is required for cell growth and apoptotic process via the regulation of proapoptotic genes (Karagianni and Wong, 2007) and is responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3, and H4) that correlates with epigenetic repression (Karagianni and Wong, 2007). This deacetylation is involved in the transcriptional regulation of genes important for cell cycle progression and development, such as p21 WAF1/cip1 (Huang et al, 2006), which was induced by amitriptyline. HDAC6 is involved in ␣-tubulin acetylation, cell motility, and proteasomal function regulation (Wickström et al, 2010).…”

Section: Discussionmentioning

confidence: 99%

The Tricyclic Antidepressant Amitriptyline Inhibits d-Cyclin Transactivation and Induces Myeloma Cell Apoptosis by Inhibiting Histone Deacetylases: In Vitro and In Silico Evidence

Mao

Hou²,

Cao³

et al. 2011

Mol Pharmacol

View full text Add to dashboard Cite

Amitriptyline is a classic tricyclic antidepressant (TCA) and has been used to treat the depression and anxiety of patients with cancer, but its relevance to cancer cell apoptosis is not known. In the present study, we demonstrated that amitriptyline inhibited cyclin D2 transactivation and displayed potential antimyeloma activity by inhibiting histone deacetylases (HDACs). Amitriptyline markedly decreased cyclin D2 promoter-driven luciferase activity, reduced cyclin D2 expression, and arrested cells at the G 0 /G 1 phase of the cell cycle. Amitriptyline-induced apoptosis was confirmed by Annexin V staining, and cleavage of caspase-3 and poly(ADP-ribose) polymerase-1. D-Cyclin expression is reported to be epigenetically regulated by histone acetylation. Thus, we examined the effects of amitriptyline on histone 3 (H3) acetylation and demonstrated that amitriptyline increased acetylation of H3 and expression of p27 and p21. Further studies indicated that amitriptyline interfered with HDAC function by down-regulation of HDAC3, -6, -7, and -8, but not HDAC2, and by interacting with HDAC7. Molecular docking analysis and molecular dynamics simulations revealed that amitriptyline bound to HDAC7 and formed strong van der Waals interactions with five residues of HDAC7, including Phe162, His192, Phe221, Leu293, and His326, thus inhibiting HDAC activity. Therefore, we found that amitriptyline inhibited cyclin D2 transactivation and HDAC activity and could be a promising treatment for multiple myeloma.

show abstract

“…This is suggested by the fact that the treatment of Namalwa cells by MTM, which inhibits all transcription factors binding to GC-rich regions (37), abolished the up-regulation of p21 WAF-1 . Sp1, whose binding to DNA is inhibited by MTM (31), is involved in the up-regulation of p21 WAF-1 in several cell types (14,38), as well as in the repression of this gene (39)(40)(41)(42). In addition, Sp3, Egr1, and Egr2 bind GC-rich regions and have been Figure 5.…”

Section: Discussionmentioning

confidence: 99%

Pomalidomide and Lenalidomide Induce p21WAF-1 Expression in Both Lymphoma and Multiple Myeloma through a LSD1-Mediated Epigenetic Mechanism

Escoubet-Lozach¹,

Lin²,

Jensen-Pergakes³

et al. 2009

Cancer Research

158

View full text Add to dashboard Cite

Lenalidomide and pomalidomide have both been evaluated clinically for their properties as anticancer agents, with lenalidomide being available commercially. We previously reported that both compounds cause cell cycle arrest in Burkitt's lymphoma and multiple myeloma cell lines by increasing the level of p21 WAF-1 expression. In the present study, we unravel the molecular mechanism responsible for p21 WAF-1 up-regulation using Namalwa cells as a human lymphoma model. We show that the increase of p21 WAF-1 expression is regulated at the transcriptional level through a mechanism independent of p53. Using a combination of approaches, we show that several GC-rich binding transcription factors are involved in pomalidomide-mediated upregulation of p21 WAF-1 . Furthermore, we report that p21 WAF-1 up-regulation is associated with a switch from methylated to acetylated histone H3 on p21 WAF-1 promoter. Interestingly, lysine-specific demethylase-1 (LSD1) silencing reduced both pomalidomide and lenalidomide up-regulation of p21 WAF-1 , suggesting that this histone demethylase is involved in the priming of the p21 WAF-1 promoter. Based on our findings, we propose a model in which pomalidomide and lenalidomide modify the chromatin structure of the p21 WAF-1 promoter through demethylation and acetylation of H3K9. This effect, mediated via LSD1, provides GC-rich binding transcription factors better access to DNA, followed by recruitment of RNA polymerase II and transcription activation. Taken together, our results provide new insights on the mechanism of action of pomalidomide and lenalidomide in the regulation of gene transcription, imply possible efficacy in p53 mutated and deleted cancer, and suggest new potential clinical uses as an epigenetic therapy.

show abstract

Histone deacetylase 3 represses p15INK4b and p21WAF1/cip1 transcription by interacting with Sp1

Cited by 42 publications

References 22 publications

Histone Deacetylase 3 (HDAC3) and Other Class I HDACs Regulate Colon Cell Maturation and p21 Expression and Are Deregulated in Human Colon Cancer

Histone Deacetylase 3 (HDAC3) and Other Class I HDACs Regulate Colon Cell Maturation and p21 Expression and Are Deregulated in Human Colon Cancer

The Tricyclic Antidepressant Amitriptyline Inhibits d-Cyclin Transactivation and Induces Myeloma Cell Apoptosis by Inhibiting Histone Deacetylases: In Vitro and In Silico Evidence

Pomalidomide and Lenalidomide Induce p21WAF-1 Expression in Both Lymphoma and Multiple Myeloma through a LSD1-Mediated Epigenetic Mechanism

Contact Info

Product

Resources

About